Outcomes
Of The 181 patients who started therapy, 135 completed chemotherapy and
radiation therapy. Of the 181 patients, 97 (54%) experienced an AS-EFS
event: 31 (32%) abandoned therapy, 28 (29%) progressed, 30 (31%)
relapsed and 8 (8%) died of toxicity. The median follow-up for the
patients who are alive and have not abandoned therapy, is 8 years (range
0-12 years).
The 5-year AS-EFS and AS-OS for the 181 eligible and evaluable patients
were, 46 ± 4% and 56 ± 4%, respectively (Figure 2A). The 5-year EFS
and OS for the cohort, were 54 ± 5% and 69 ± 4% , respectively (Figure
2B). The 5-year AS-EFS rates by stage were: stage II 65 ± 8%, stage III
52 ± 7%, and stage IV 22 ± 6% (p=0.0001) (Figure 3A). The 5-year AS-OS
rates by stage were: stage II 76 ± 7%, stage III 59 ± 7%, and stage IV
35 ± 7% (p=0.0006) (Figure 3B). When abandonment is censored, 5-year
EFS rates by stage were: stage II 73 ± 8%, stage III 62 ± 7% and stage
IV 25 ± 7% (p<0.0001) (Figure 4A); 5-year OS rates by stage
were: stage II 87 ± 6%, stage III 74 ± 6%, and stage IV 43 ± 8%
(p<0.0001) (Figure 4B).